+Follow
神秘紫
No personal profile
2
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
神秘紫
2021-07-06
Nice
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087179126205260","uuid":"4087179126205260","gmtCreate":1624104992309,"gmtModify":1624880835567,"name":"神秘紫","pinyin":"smzshenmizi","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":157350240,"gmtCreate":1625568030480,"gmtModify":1703743904325,"author":{"id":"4087179126205260","authorId":"4087179126205260","name":"神秘紫","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087179126205260","authorIdStr":"4087179126205260"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157350240","repostId":"2149333886","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":157350240,"gmtCreate":1625568030480,"gmtModify":1703743904325,"author":{"id":"4087179126205260","authorId":"4087179126205260","name":"神秘紫","avatar":"https://static.tigerbbs.com/8a1a172d1a6a97bd0845231616bcef1e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087179126205260","authorIdStr":"4087179126205260"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157350240","repostId":"2149333886","repostType":4,"repost":{"id":"2149333886","kind":"highlight","pubTimestamp":1625567714,"share":"https://ttm.financial/m/news/2149333886?lang=&edition=fundamental","pubTime":"2021-07-06 18:35","market":"hk","language":"zh","title":"爱科百发赴港IPO:年亏9163万,尚未产品商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2149333886","media":"格隆汇","summary":"上海爱科百发生物医药技术股份有限公司(以下简称“爱科百发”)向港交所递交上市招股说明书,美银、中信证券和华兴资本担任联席保荐人,德勤为其审计师。\n自2014年成立以来,爱科百发共开展了8轮融资。在最新","content":"<p>上海爱科百发生物医药技术股份有限公司(以下简称“爱科百发”)向港交所递交上市招股说明书,美银、<a href=\"https://laohu8.com/S/600030\">中信证券</a>和华兴资本担任联席保荐人,德勤为其审计师。</p>\n<p>自2014年成立以来,爱科百发共开展了<b>8轮融资</b>。在最新的C+轮融资中,2021年1月,公司引入高瓴创投、TPG联合领投,万容红土、瑞华投资、燕园姚商等8家投资机构参与投资,<b>融资后公司估值达到38.7亿元</b>。</p>\n<p>IPO前,公司股权架构方面,Jim Zhen WU博士通过全资拥有的Prots Excel持股19.58%,通过全资拥有的Million Joy持股4.99%,通过持股99.99%的爱尔凯持股2.65%,合计拥有股份27.22%;4个雇员持股计划平台合计持股7.96%;机构投资者中,<b>启明创投持股占比最大,达11.11%</b>;泰福资本通过Golden Trend、HarmonySky合计持股7.84%;晨兴资本通过耀阳生物科技持股7.51%;<b>高瓴资本、TPG各持有公司4.99%股权</b>,除此之外,其他股东持股约31%。</p>\n<p><img src=\"https://static.tigerbbs.com/7b431d82c25aa99e56762dcca708a2c2\" tg-width=\"1118\" tg-height=\"676\" referrerpolicy=\"no-referrer\"></p>\n<p>业务方面,爱科百发作为一家创新生物制药公司,专注于发现和开发新型疗法,以应对呼吸系统和肺部疾病方面未被满足的医疗需求。</p>\n<p>目前,爱科百发已开发了<b>9种候选药物的产品管线</b>,核心产品包括以Ziresovir为首的三项药物RSV药品组合,以及以AK3280为重点的三项药物的抗纤维化药品组合。除此之外,公司在肺纤维化和炎症、肝脏及其他疾病领域还有多款在研药品处于临床前或临床阶段,离上市还有很长的时间。</p>\n<p><img src=\"https://static.tigerbbs.com/1abd4768a9678b36257ed9350d5fec2e\" tg-width=\"1064\" tg-height=\"669\" referrerpolicy=\"no-referrer\"></p>\n<p>2020年,全球RSV药物市场为18亿美元,<b>预计到2030年将增长至18亿美元</b>,年复合增长率为21.4%。目前,<b>市场上还没有有效的RSV治疗方法</b>。而爱科百发正研发的Ziresovir是全球首款成功完成住院婴幼儿II期概念验证临床试验的RSV药物。</p>\n<p>临床试验显示,多剂量服用Ziresovir后,患者体内有强抗病毒作用,与安慰剂组相比,药物治疗组的病毒载量最多减少98%,显示出良好的疗效及安全性。目前,<b>针对儿童RSV的AK0529药物(Ziresovir)已处于临床III期,预计将于2022年下半年向国家药监局提交新药申请,并于2023年在国内上市。</b></p>\n<p><img src=\"https://static.tigerbbs.com/adefd4a0d734b6768bbede484a81ad6e\" tg-width=\"773\" tg-height=\"704\" referrerpolicy=\"no-referrer\"></p>\n<p>就目前而言,爱科百发尚未有产品上市商业化,<b>仍处于亏损状态</b>。招股书显示,公司2019年无营收,2020年营收为1415万元;相对应的净亏损分别为1.12亿元、9162.8万元。<b>截至2021年一季度,公司亏损规模较上年同期扩大1倍至3525.8万元</b>。可以预见的是,短时间内,公司“烧钱”研发的状况仍将持续。</p>","source":"gelonghui_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>爱科百发赴港IPO:年亏9163万,尚未产品商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n爱科百发赴港IPO:年亏9163万,尚未产品商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-06 18:35 北京时间 <a href=http://www.gelonghui.com/p/473496><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>上海爱科百发生物医药技术股份有限公司(以下简称“爱科百发”)向港交所递交上市招股说明书,美银、中信证券和华兴资本担任联席保荐人,德勤为其审计师。\n自2014年成立以来,爱科百发共开展了8轮融资。在最新的C+轮融资中,2021年1月,公司引入高瓴创投、TPG联合领投,万容红土、瑞华投资、燕园姚商等8家投资机构参与投资,融资后公司估值达到38.7亿元。\nIPO前,公司股权架构方面,Jim Zhen ...</p>\n\n<a href=\"http://www.gelonghui.com/p/473496\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","relate_stocks":{"HSI":"恒生指数"},"source_url":"http://www.gelonghui.com/p/473496","is_english":false,"share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","article_id":"2149333886","content_text":"上海爱科百发生物医药技术股份有限公司(以下简称“爱科百发”)向港交所递交上市招股说明书,美银、中信证券和华兴资本担任联席保荐人,德勤为其审计师。\n自2014年成立以来,爱科百发共开展了8轮融资。在最新的C+轮融资中,2021年1月,公司引入高瓴创投、TPG联合领投,万容红土、瑞华投资、燕园姚商等8家投资机构参与投资,融资后公司估值达到38.7亿元。\nIPO前,公司股权架构方面,Jim Zhen WU博士通过全资拥有的Prots Excel持股19.58%,通过全资拥有的Million Joy持股4.99%,通过持股99.99%的爱尔凯持股2.65%,合计拥有股份27.22%;4个雇员持股计划平台合计持股7.96%;机构投资者中,启明创投持股占比最大,达11.11%;泰福资本通过Golden Trend、HarmonySky合计持股7.84%;晨兴资本通过耀阳生物科技持股7.51%;高瓴资本、TPG各持有公司4.99%股权,除此之外,其他股东持股约31%。\n\n业务方面,爱科百发作为一家创新生物制药公司,专注于发现和开发新型疗法,以应对呼吸系统和肺部疾病方面未被满足的医疗需求。\n目前,爱科百发已开发了9种候选药物的产品管线,核心产品包括以Ziresovir为首的三项药物RSV药品组合,以及以AK3280为重点的三项药物的抗纤维化药品组合。除此之外,公司在肺纤维化和炎症、肝脏及其他疾病领域还有多款在研药品处于临床前或临床阶段,离上市还有很长的时间。\n\n2020年,全球RSV药物市场为18亿美元,预计到2030年将增长至18亿美元,年复合增长率为21.4%。目前,市场上还没有有效的RSV治疗方法。而爱科百发正研发的Ziresovir是全球首款成功完成住院婴幼儿II期概念验证临床试验的RSV药物。\n临床试验显示,多剂量服用Ziresovir后,患者体内有强抗病毒作用,与安慰剂组相比,药物治疗组的病毒载量最多减少98%,显示出良好的疗效及安全性。目前,针对儿童RSV的AK0529药物(Ziresovir)已处于临床III期,预计将于2022年下半年向国家药监局提交新药申请,并于2023年在国内上市。\n\n就目前而言,爱科百发尚未有产品上市商业化,仍处于亏损状态。招股书显示,公司2019年无营收,2020年营收为1415万元;相对应的净亏损分别为1.12亿元、9162.8万元。截至2021年一季度,公司亏损规模较上年同期扩大1倍至3525.8万元。可以预见的是,短时间内,公司“烧钱”研发的状况仍将持续。","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}